Human epidermal growth factor receptor type 2 protein expression in Chinese metastatic prostate cancer patients correlates with cancer specific survival and increases after exposure to hormonal therapy

Asian Journal of Andrology

Volumn 10, Issue 5, 2008, Pages 701-709

  Dai, Bo ^a   Kong, Yun Yi ^a   Ye, Ding Wei ^a   Ma, Chun Guang ^a   Zhou, Xiao Yan ^a   Yao, Xu Dong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Gene amplification; Human epidermal growth factor receptor type 2; Immunohistochemistry; Prognosis; Prostate cancer; Prostatic neoplasms

Indexed keywords

BICALUTAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUTAMIDE; GONADORELIN AGONIST; KETOCONAZOLE; MITOXANTRONE; PREDNISONE;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER SURVIVAL; CHINESE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEATH; DRUG EXPOSURE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; ORCHIECTOMY; PREDICTION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TRANSURETHRAL RESECTION;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ASIAN CONTINENTAL ANCESTRY GROUP; BIOPSY; CHINA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RECEPTOR, ERBB-2; RISK FACTORS;

EID: 50149100357     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1111/j.1745-7262.2008.00433.x     Document Type: Article

References (21)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics 2007. CA Cancer J Clin 2007; 57: 43-66.
2. Shanghai Municipal Center for Disease Control & Prevention Incidence of malignant tumors of city Shanghai in the year 2002. Chinese Tumor 2006; 26: 496.
3. Dai B, Ye DW, Kong YY, Shen YJ, Wang BH. Individualized prostate biopsy strategy for Chinese patients with different prostate-specific antigen levels. Asian J Androl 2008; 10: 325-31.
4. Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004; 351: 1488-90.
5. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51.
6. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer though modulation of androgen receptor signaling by the Her-2/neu tyrosine kinase. Nat Med 1999; 3: 280-5.
7. Montironi R, Mazzucchelli R, Barbisan F, Stramazzotti D, Santinelli A, Scarpelli M, et al. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: Comparison with clinically detected androgen-dependent and androgen-independent cancer. Hum Pathol 2006; 37: 1137-44.
8. Sanchez KM, Sweeney CJ, Mass R, Koch MO, Eckert GJ, Geary WA, et al. Evaluation of HER-2/neu expression in prostatic adenocarcinoma: A request for a standardized, organ specific methodology. Cancer 2002; 95: 1650-5.
9. Lara PN, Chee KG, Longmate J, Ruel C, Meyers FJ, Gray, C. R., et al. rastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase H Trial. Cancer 2004; 100: 2125-31.
10. Carles J, Lloreta J, Salido M, Font A, Suarez M, Baena V, et al. Her-2/ neu expression in prostate cancer: A dynamic process? Clin Cancer Res 2004; 10: 4742-5.
11. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20.
12. Ye D, Mendelsohn J, Fan Z. Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27 and costimulate proliferation of MDA PCA 2a and MDA PCA 2b prostate cancer cells. Clin Cancer Res 1999; 5: 2171-7.
13. Ross JS, Sheehan CE, Hayner-Buchan AM, Ambros RA, Kallakury BV, Kaufman RP Jr, et al. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer 1997; 79: 2162-70.
14. Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000; 92: 1918-25.
15. Oxley JD, Winkler MH, Gillatt DA, Peat DS. Her-2/neu oncogene amplification in clinically localised prostate cancer. J Clin Pathol 2002; 55: 118-20.
16. Shi Y, Brands FH, Chatterjee S, Feng AC, Groshen S, Schewe J, et al. Her-2/neu expression in prostate cancer: High level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol 2001; 166: 1514-9.
17. Jorda M, Morales A, Ghorab Z, Fernandez G, Nadji M, Block N. Her2 expression in prostatic cancer: A comparison with mammary carcinoma. J Urol 2002; 168: 1412-4.
18. Nishio Y, Yamada Y, Kokubo H, Nakamura K, Aoki S, Taki T. Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer. Urology 2006; 68: 110-5.
19. Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 2004; 17: 292-306.
20. Berger R, Lin DI, Nieto M, Sicinska E, Garraway LA, Adams H, et al. Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res 2006; 66: 5723-8.
21. Ziada A, Barqawi A, Glode LM, Varella-Garcia M, Crighton F, Majeski S, et al. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 2004; 60: 332-7.